Rein Therapeutics, Inc.
For the period ended Jun 30, 2026. Filed Aug 14, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 14, 2026
RNTX$0.59-5.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(In thousands)
| Six Months Ended June 30, | ||
|---|---|---|
| 2026 | 2025 | |
| Cash flows from operating activities: | ||
| Net loss | $(12,213) | $(12,323) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization expense | — | 1 |
| Net amortization of discount on notes payable | 1,075 | — |
| Non-cash warrant issuance cost | 423 | — |
| Changes in fair value of warrant liabilities | 8 | — |
| Accretion of discount on investments | (12) | — |
| Stock-based compensation expense | 320 | 520 |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | 305 | (115) |
| Other assets | (1,708) | (2,344) |
| Accounts payable | 400 | 5,117 |
| Accrued expenses and other current liabilities | (662) | (3,172) |
| Other long-term liabilities | — | (277) |
| Net cash used in operating activities | (12,064) | (12,593) |
| Cash flows from investing activities: | ||
| Purchases of short-term investments | (32,094) | — |
| Purchases of long-term investments | (2,979) | — |
| Net cash used in investing activities | (35,073) | — |
| Cash flows from financing activities: | ||
| Proceeds from issuance of common stock, net of offering costs | 53,544 | 367 |
| Proceeds from notes payable | 4,300 | — |
| Repayment of notes payable | (5,375) | — |
| Proceeds from issuance of common stock in connection with stock option exercises | — | 1 |
| Proceeds from issuance of common stock in connection with warrant exercises | — | 1,595 |
| Proceeds from issuance of warrants, net of offering costs | — | 481 |
| Proceeds from warrant exchanges, net of offering costs | — | 2,984 |
| Proceeds from warrant exercises with common stock subscribed | — | 22 |
| Net cash provided by financing activities | 52,469 | 5,450 |
| Effect of exchange rate changes on cash and cash equivalents | (5) | — |
| Net increase (decrease) in cash and cash equivalents | 5,327 | (7,143) |
| Cash and cash equivalents at beginning of period | 3,215 | 12,865 |
| Cash and cash equivalents at end of period | $8,542 | $5,722 |
| Supplemental disclosure of non-cash investing and financing activities: | ||
| Unrealized loss on investments | $(12) | $(33) |
| Foreign currency translation adjustments | $5 | $7 |
| Initial recognition of warrant liability | $3,693 | $— |
| Allocate net value of warrants issued in connection with the May 2026 Offering | $(3,263) | $— |
| Warrant issuance cost recognized as expense | $(423) | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.